Zanidatamab is currently being evaluated in clinical trials in multiple HER2 overexpressing solid tumors, including a registration-enabling clinical trial in HER2 gene amplified biliary tract cancer (NCT04466891). Here, ERBB2 is linked to biliary tract neoplasm.